The resistance of bacterial pathogens to antibiotic treatment has emerged as one of the central threats to public health in the 21st century.[1] At the same time, the surge of bacterial drug resistance has been paralleled by a decline in antibacterial drug discovery research in most of the pharmaceutical industry,[1, 2] a decline which has led to a general current paucity of agents (or the complete absence thereof) with satisfactory activity against major ...